{"name":"CUTISS AG","slug":"cutiss-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"denovoSkin(TM)","genericName":"denovoSkin(TM)","slug":"denovoskin-tm","indication":"Treatment of severe burns","status":"phase_3"},{"name":"EHSG-KF","genericName":"EHSG-KF","slug":"ehsg-kf","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"denovoSkin(TM)","genericName":"denovoSkin(TM)","slug":"denovoskin-tm","phase":"phase_3","mechanism":"denovoSkin(TM) is a regenerative medicine treatment that uses a patient's own skin cells to repair damaged skin.","indications":["Treatment of severe burns"],"catalyst":""},{"name":"EHSG-KF","genericName":"EHSG-KF","slug":"ehsg-kf","phase":"phase_2","mechanism":"The specific mechanism of action for EHSG-KF is not publicly disclosed.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQcE9haEJ3RmZSdERrU3BaZlVQN1BWSERpN3M2SGpuVTJ1NmQ3NjNiUDJaVVQyaXU0SThyeFFBN1VzaVktQU5uc20xbTUwNFdqMDlMUkhvZk43OUp5WXF4S25GUXNXd2FNTi13TVpCNmpHYi1QV2d0UExwM3hQR19NdlBKZkVBSkJOUUsyc1R1d2IxajlD?oc=5","date":"2026-03-23","type":"trial","source":"openPR.com","summary":"Burns Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight - openPR.com","headline":"Burns Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOQVJvZmZXNVRWT0lwYlpTTGVZVmFlNXR6a0liSjRHOTBXUHFad18tWVNFNTRteXRSbEEtQ3R0aFp3LUg3YXE3eFd5OXd4UXBacm1vV3BWQVJMUUJtekJJc21EQXZsUUZkbElXcmpBVjZabnV4aXB4Y21LZDJBM1VnMWJxMk9tQnBJVlllVHlLYWxtUUJiUWNnYnpnMzdhSEFueFE?oc=5","date":"2025-12-09","type":"pipeline","source":"Startupticker.ch","summary":"Promising progress for therapies against critical medical needs - Startupticker.ch","headline":"Promising progress for therapies against critical medical needs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNQlY3Si1MMHVJMXYxOHdtVVJ6bDhqQ0plVl9KcE1kTlhsN0ZncTJjVkZJQmQ0Wk1EUkVCZDZJYUo3bFlvSFZaRF9qZjZMdGhzTkdhOFF1VUp2MTJQV090eWNwMEtpNmpfc1FVY3lOb0hITlh3YTFvNFhibTV4TjJ2RUhZUEZCUTBodERwa0psekpuMmMxRDZaRjFQU01PSzA?oc=5","date":"2025-09-10","type":"pipeline","source":"Tech.eu","summary":"CUTISS secures €57.9M Series C to advance regenerative skin therapies - Tech.eu","headline":"CUTISS secures €57.9M Series C to advance regenerative skin therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPUFd5T3lENHNBX2pKVlR5TmNxRG1DVWpHNUJ5LUJZRjhQTS1XNnF0bVhiQVN3THUxZFZ4ZzgwYlVpVWltZ1BqRzlpZlNoSzQyR1pyUjhoMHpidjhnbW9TQzNzNlozZkpZTGlGT3dvSXRyYnc0OW4zekxyRnctaHY2UUdUSm1URzQtOFpyUHh1Rk83QnVoYTlmUklKRk92cE4yd3pydXdYVnlIOXh5SWxB?oc=5","date":"2025-09-10","type":"trial","source":"Startupticker.ch","summary":"CUTISS raises additional CHF 31 million to support ongoing Phase 3 trials - Startupticker.ch","headline":"CUTISS raises additional CHF 31 million to support ongoing Phase 3 trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPOWRyLVdUYTBjckhWcU5haFRHOW9Tdlk3bi1ua2Nuc3pmSFM5OENvamU2RnplZGJnUnlGX01kV0dhMEtYbU5MVjZzRGV3Z0prOUlHRVltVmhQSGxmSFZoRDUzN0JiTy1teVdiQlNmTzR0UW1mTk43WlhNNXhncXhqRTBHNlFGTEZWMVVldGhBT3NCbUR5Vm5NMU5hWDRhWHZmWEdCaQ?oc=5","date":"2024-05-21","type":"trial","source":"Startupticker.ch","summary":"CUTISS attracts CHF 25 million and enters Phase 3 clinical trials - Startupticker.ch","headline":"CUTISS attracts CHF 25 million and enters Phase 3 clinical trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUHkxSmh6bFBoT053T2tSdWEyQXZ1YWQ4ejZTSlZaUVl1NkVRV1FNSFhRazJFUXpWc1F2UXdSdmNKRlRtR0p5b2xLdXJvNVRXc285OV9rUnkwdmZDUFllUDlXeG5wZEpmRWUtdGFRdGZ2U1FGTnIwaVZmVzU2U05WT1VQN0JUMUNmdnZKZEY5X3JCb0RheHhCT0xqZ2ZXbTdiOGhEOThkbzdYMlU?oc=5","date":"2023-04-28","type":"pipeline","source":"Startupticker.ch","summary":"Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million - Startupticker.ch","headline":"Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNMGp1U280V2JCN0s5MlltZjFNRlVvVUJKNXp6aWVkdTQ3ZTQ4d0t2b2Y0RlBNaDF3Q05sSzhJQTVsVzFmYUp4V0hxczg2OW0tOUVTZzJhb3p3MW5GcHF5TE92UGw5S0VkT2c3QVFic0lTTkZfa3VXajQ4RFFrbjBJakhEVE9Ba1g3eHFNaUQzbnlNeWFTM291MlItZ2RQMUgtWExPSUN3QjFXNFk1emlR?oc=5","date":"2020-03-16","type":"pipeline","source":"Innovation News Network","summary":"CUTISS on the challenges and opportunities in regenerative therapy - Innovation News Network","headline":"CUTISS on the challenges and opportunities in regenerative therapy","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}